HomeComparePHGUF vs ORCC

PHGUF vs ORCC: Dividend Comparison 2026

PHGUF yields 132.45% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHGUF wins by $13.51M in total portfolio value
10 years
PHGUF
PHGUF
● Live price
132.45%
Share price
$1.51
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13.53M
Annual income
$5,443,687.21
Full PHGUF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — PHGUF vs ORCC

📍 PHGUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHGUFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHGUF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHGUF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHGUF
Annual income on $10K today (after 15% tax)
$11,258.28/yr
After 10yr DRIP, annual income (after tax)
$4,627,134.13/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, PHGUF beats the other by $4,627,133.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHGUF + ORCC for your $10,000?

PHGUF: 50%ORCC: 50%
100% ORCC50/50100% PHGUF
Portfolio after 10yr
$6.78M
Annual income
$2,721,844.13/yr
Blended yield
40.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

PHGUF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
51.7
Piotroski
6/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHGUF buys
0
ORCC buys
0
No recent congressional trades found for PHGUF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHGUFORCC
Forward yield132.45%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$13.53M$21.4K
Annual income after 10y$5,443,687.21$1.04
Total dividends collected$12.40M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: PHGUF vs ORCC ($10,000, DRIP)

YearPHGUF PortfolioPHGUF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$23,945$13,245.03$11,190$489.61+$12.8KPHGUF
2$55,262$29,640.44$12,229$256.01+$43.0KPHGUF
3$123,061$63,930.66$13,216$130.74+$109.8KPHGUF
4$264,727$133,051.80$14,207$66.02+$250.5KPHGUF
5$550,752$267,494.95$15,234$33.17+$535.5KPHGUF
6$1,109,410$520,104.50$16,317$16.62+$1.09MPHGUF
7$2,166,203$979,134.42$17,468$8.32+$2.15MPHGUF
8$4,104,595$1,786,757.87$18,695$4.16+$4.09MPHGUF
9$7,556,038$3,164,121.24$20,006$2.08+$7.54MPHGUF
10$13,528,648$5,443,687.21$21,407$1.04+$13.51MPHGUF

PHGUF vs ORCC: Complete Analysis 2026

PHGUFStock

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Full PHGUF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this PHGUF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHGUF vs SCHDPHGUF vs JEPIPHGUF vs OPHGUF vs KOPHGUF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.